All In Biotech

Drug Trial Radar · NCT04381468

SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD): A Multi-center, Randomized, Double-Blind, Placebo-Controlled Safety and Biomarker Study of Pepinemab Anti-SEMA4D Antibody in Early-AD

Last checked: Nov 19, 2026Latest source record: Aug 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Jul 22, 2021

Primary completion

Jun 5, 2024

Study completion Jun 5, 2024

Sponsor

Lead sponsor
Vaccinex Inc.Industry
Sponsor type
Industry
Collaborators
Alzheimer's Drug Discovery Foundation; Alzheimer's Association
First posted
May 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate safety, tolerability, the effects on cognition and brain metabolism of pepinemab in early AD dementia (early AD) subjects.

Conditions

  • Alzheimer Disease

Interventions

  • PepinemabDrug

    Pepinemab is a humanized IgG4 monoclonal antibody. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80

  • PlaceboDrug

    Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with treatment emergent adverse events (TEAEs)Time frame: Up to 40 weeks

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Pacific Research Network, Inc

    San Diego, California

  • Georgetown University

    Washington D.C., District of Columbia

  • Brain Matters Research

    Delray Beach, Florida

  • Neuropsychiatric Research Center of Southwest Florida

    Fort Myers, Florida

  • JEM Research Institute

    Lake Worth, Florida

  • Premiere Research Institute of Palm Beach, Neurology

    Palm Beach, Florida

  • Brain Matters Research

    Stuart, Florida

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • University of Kansas Medical Center

    Fairway, Kansas

  • Neurological Associates of Albany

    Albany, New York

  • Dent Neurological Associates

    Amherst, New York

  • Columbia University Irving Medical Center

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • Re-Cognition Health

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.